- Home
- PRVA vs HCM Comparison
PRVA vs HCM Comparison
Compare PRVA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRVA | HCM |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRVA | HCM |
|---|---|---|
| Price | $22.87 | $14.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 12 |
| Target Price | ★ $31.47 | $20.59 |
| AVG Volume (30 Days) | ★ 1.2M | 45.2K |
| Earning Date | 11-05-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $2,122,842,000.00 | N/A |
| Revenue This Year | $15.81 | $14.24 |
| Revenue Next Year | $9.73 | $11.52 |
| P/E Ratio | $255.78 | ★ $5.49 |
| Revenue Growth | ★ 22.26 | N/A |
| 52 Week Low | $18.92 | $9.77 |
| 52 Week High | $28.82 | $16.33 |
Technical Indicators
Market Signals| Indicator | PRVA | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 73.66 | 58.65 |
| Support Level | $22.59 | $13.93 |
| Resistance Level | $23.99 | $15.14 |
| Average True Range (ATR) | 0.56 | 0.33 |
| MACD | 0.31 | 0.00 |
| Stochastic Oscillator | 92.50 | 78.31 |
Price Performance
Historical ComparisonAbout PRVA Privia Health Group Inc.
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.